학술논문

Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment
Document Type
article
Source
Clinical Infectious Diseases. 76(3)
Subject
Lung
Infectious Diseases
Prevention
Pneumonia & Influenza
Emerging Infectious Diseases
Immunization
Vaccine Related
Pneumonia
Biodefense
Good Health and Well Being
Humans
COVID-19
SARS-CoV-2
Ritonavir
COVID-19 Drug Treatment
treatment rebound
COVID-19 recrudescence
nirmatrelvir
Omicron
Biological Sciences
Medical and Health Sciences
Microbiology
Language
Abstract
We isolated a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2 variant from a person with coronavirus disease 2019 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing were performed with both parental SARS-CoV-2 and multiple variants of concern. We found that neither nirmatrelvir resistance nor absence of neutralizing immunity was a likely cause of the recrudescence.